Available credits: 0.25
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Sara A. Hurvitz, MD, FACP
Contracted research: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer HealthCare Pharmaceuticals, Biosplice Therapeutics, Inc., CytomX Therapeutics, Inc., Daiichi Sankyo, Co., Ltd., Dantari, Inc., Dignitana, G1 Therapeutics, Inc., Genentech, Gilead Sciences, Inc., GlaxoSmithKline, Greenwich Lifesciences, Inc., Immunomedics, Inc., Lilly, MacroGenics, Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Inc., Orinove Inc., Orum Therapeutics, Pfizer Inc., Phoenix Molecular Designs, Pieris Pharmaceuticals, Inc., Puma Biotechnology, Inc., Radius Health, Inc., Sanofi-aventis U.S. Inc., Seattle Genetics, Zymeworks Inc.
Narjust Florez, MD
Consulting fees/advisory boards: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Mirati Therapeutics, Inc., NeoGenomics Laboratories, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc.
Jennifer Caudle, DO
Fees received for promotional/non-CME/CE activities: GlaxoSmithKline, Janssen Pharmaceuticals, Inc. , Johnson & Johnson, Pfizer, Inc., Reckitt Benckiser Group plc, Salix Pharmaceuticals, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): GlaxoSmithKline, Moderna, Inc., Pfizer, Inc.
The activity planners, peer reviewers, and staff have no financial relationships to disclose.
This activity is intended for oncologists, nurse practitioners, and physician assistants.
Upon completion, participants should be able to:
- Cite efficacy and safety data for novel HER3-targeted agents that are in clinical development for breast and lung cancers
- Integrate the latest clinical data regarding the efficacy and safety of HER3-targeted agents into practice as they become available
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Any literature links included in this activity are provided as a convenience and for informational purposes only; they are not intended and should not be construed as legal or medical advice, nor are they endorsements of any healthcare provider, practice, professional organization, or medical journal. Med‑IQ bears no responsibility for the accuracy, legality, or content of external sites or for that of subsequent links. Accessing such links will take you out of this educational activity. Contact the external sites for answers to questions regarding their content.
COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?1.00 program credit
Yelena Janjigian, MD
Roy F. Chemaly, MD, MPH